BlackRock Fund Advisors recently announced the acquisition of new stake in BioDelivery Sciences International Inc. (NASDAQ:BDSI). The institutional investor has increased its shareholding in the Healthcare company by 8.93% to 6.78 million shares with purchase of 0.56 million shares. This fresh investment now brings its stake to 6.77% valued currently at $28.42 million. In addition, Deerfield Management Company LP raised its holdings by 0.36 million to 6.55 million shares. And The Vanguard Group, Inc. has lifted its position by 21.66% or 0.79 million shares – to 4.41 million shares.
With over 2.8 million BioDelivery Sciences International Inc. (BDSI) shares trading Friday and a closing price of $3.81 on the day, the dollar volume was approximately $10.68 million. The shares have shown a negative weekly performance of -19.28% and its price on 08/28/20 lost nearly -3.54%. Currently, there are 100.14M common shares owned by the public and among those 98.38M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for BDSI have a consensus price objective of $8.00. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $7.00 should the stock experience a downside. Incidentally, analysts’ outlook for the BioDelivery Sciences International Inc. stock is 1.70 for the next 12 months. But an upside of 57.67% will see the stock hit the forecast high price target while mean target price for the stock is $8.00.
Insiders at the company have transacted a total of 87 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 35 of these insider trades were purchases, accounting for 6,811,143 shares. Insider sales of the common stock occurred on 52 occasions, with total insider shares sold totaling 7,807,393 shares.
The top 3 mutual fund holders in BioDelivery Sciences International Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Emerald Growth Fund. Vanguard Total Stock Market Index owns 2.87 million shares of the company’s stock, all valued at over $12.01 million. iShares Russell 2000 ETF sold 87346.0 shares to see its total holdings shrink to 1.87 million shares valued at over $7.83 million and representing 1.87% of the shares outstanding. Emerald Growth Fund now owns shares totaling to 1.18% of the shares outstanding.
Shares of BioDelivery Sciences International Inc. (NASDAQ: BDSI) opened at $3.99, up $0.04 from a prior closing price of $3.95. However, the script later closed the day at $3.81, down -3.54%. The company’s stock has a 5-day price change of -19.28% and -20.95% over the past three months. BDSI shares are trading -39.72% year to date (YTD), with the 12-month market performance down to -11.19% lower. It has a 12-month low price of $2.85 and touched a high of $7.21 over the same period. Currently, 2.8 million shares have been traded, compared to an average intraday trading volume of 1.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.24%, -14.35%, and -22.89% respectively.
Institutional ownership of BioDelivery Sciences International Inc. (NASDAQ: BDSI) shares accounts for 78.50% of the company’s 100.14M shares outstanding. Mutual fund holders own 24.22%, while other institutional holders and individual stakeholders account for 51.96% and 10.64% respectively.
It has a market capitalization of $398.72M and a beta (3y monthly) value of 0.59. The stock’s trailing 12-month PE ratio is 71.89, while the earnings-per-share (ttm) stands at $0.05. The company has a PEG of 2.88 and a Quick Ratio of 2.50 with the debt-to-equity ratio at 0.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.30% over the week and 6.70% over the month.
Analysts forecast that BioDelivery Sciences International Inc. (BDSI) will achieve an EPS of $0.06 for the current quarter, $0.06 for the next quarter and $0.43 for 2021. The lowest estimate earnings-per-share for the quarter is $0.04 while analysts give the company a high EPS estimate of $0.07. Comparatively, EPS for the current quarter was $0 a year ago. Earnings per share for the fiscal year are expected to increase by 74.90%, and 144.00% over the next financial year. EPS should shrink at an annualized rate of 25.00% over the next five years, compared to 30.30% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate BioDelivery Sciences International Inc. (BDSI) as a “Strong Buy” at a consensus score of 1.70. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 0 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BDSI, a number of firms have released research notes about the stock. Northland Capital stated their Outperform rating for the stock in a research note on April 22, 2020, with the firm’s price target at $9. Piper Sandler coverage for the BioDelivery Sciences International Inc. (BDSI) stock in a research note released on January 09, 2020 offered a Overweight rating with a price target of $9. SunTrust was of a view on March 20, 2019 that the stock is Buy, while Janney gave the stock Buy rating on January 31, 2019, issuing a price target of $5. Seaport Global Securities on their part issued Buy rating on January 26, 2018.